Temozolomide dosing regimens for glioma patients (Q37995906)

26 August 2017

title

Temozolomide dosing regimens for glioma patients (English)

1 reference

26 August 2017

0 references

Herwig M Strik

1

1 reference

26 August 2017

Christine Marosi

series ordinal

2

1 reference

26 August 2017

Bernd Kaina

series ordinal

3

1 reference

26 August 2017

Bart Neyns

series ordinal

4

1 reference

26 August 2017

publication date

1 June 2012

1 reference

Current Neurology and Neuroscience Reports

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

286-293

1 reference

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

MGMT: its role in cancer aetiology and cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Extended-schedule dose-dense temozolomide in refractory gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

A phase I trial of weekly lomustine in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0262-Y

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

21 January 2018

1 reference

12 December 2020

Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs

1 reference

12 December 2020

DNA repair in resistance to alkylating anticancer drugs

1 reference

12 December 2020

Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas

1 reference

12 December 2020

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

1 reference

12 December 2020

10.1007/S11910-012-0262-Y

Identifiers

DOI

1 reference

26 August 2017

1 reference